Loading...
Ozempic Patent Expiry Triggers Semaglutide Boom: Over 50 Brands Enter Indian Pharma
LIVE TV
LOCAL
Tour
ENGLISH
For You
Entertainment
National
Sports
Markets
Business & Economy
Lifestyle
World
Astrology & Religion
Technology
Education & Jobs
Auto
Politics
Viral
Opinions
Loading more articles...
Home
Local
Live TV
Ozempic Patent Expires: Indian Pharma Unleashes 'Sema' Storm with 50+ Generic Brands, Prices to Halve
N
News18
•
06-03-2026, 12:54
Ozempic Patent Expires: Indian Pharma Unleashes 'Sema' Storm with 50+ Generic Brands, Prices to Halve
•
Ozempic's semaglutide patent expires next week in India, triggering a rush of generic versions.
•
Over 50 Indian pharmaceutical companies are set to launch their own semaglutide brands, many named with 'Sema' prefix or suffix.
•
Prices for semaglutide are expected to drop by 30-50% initially, potentially reaching 70-75% reduction over time.
•
This increased affordability will significantly expand access to GLP-1 therapy for diabetes and obesity patients.
•
Manufacturing semaglutide, a complex injectable peptide, poses technical challenges, emphasizing quality and delivery devices.
Read Full Article on News18 in English
✦
More like this
✦
More like this
Semaglutide Patent Expires: Generics Flood Market, Prices Plummet 50-70%
M
Moneycontrol
Diabetes Treatment Revolution: Natco Pharma Launches Affordable Semaglutide in India
N
News18
Abbott Partners with Novo Nordisk to Launch Extensior, Expanding Diabetes Care in India
M
Moneycontrol
Low-Cost Anti-Obesity Drugs Coming to India as Semaglutide Patent Expires
F
Firstpost
Eris, Natco Launch Generic Semaglutide Brands as Patent Expires, Boosting Affordability
N
News18
Obesity Drug Patent Ends: Prices to Drop to Rs 500, A Game-Changer for India
N
News18
